Literature DB >> 3416897

Cytofluorescence localization and disposition of doxorubicin and doxorubicinol in rat cardiac tissue.

R Danesi1, A Paparelli, N Bernardini, M Del Tacca.   

Abstract

The localization of cardiac cytofluorescence and tissue levels of doxorubicin (DXR) and doxorubicinol (DXR-ol) were studied in rats treated with a single (9 mg/kg: 1-day study) or 3 weekly doses (3 mg/kg: 7-week study) of the compounds. A striking orange-red fluorescence was observed in cardiac cell nuclei from DXR 1-day rats, whilst heart cells from DXR-ol 1-day rats displayed a faint, diffuse fluorescence. Neither cardiac tissue from DXR nor from DXR-ol 7-week animals showed any drug-specific fluorescence. HPLC assay showed that in DXR 1-day rats the drug was concentrated in the heart, which also contained the endogenously produced DXR-ol. Plasma levels of DXR-ol were initially high in DXR-ol 1-day rats but rapidly decreased with time; cardiac levels of DXR-ol remained low. Hearts from DXR 7-week rats contained appreciable amounts of DXR and DXR-ol, while very low levels of DXR-ol were found in DXR-ol 7-week animals. The data correlated well with the ECG alterations recorded during the study, which were more severe in DXR- than in DXR-ol-treated rats. These results indicate that the lower tissue uptake of exogenously administered DXR-ol might explain its lower toxic cardiac potential compared with DXR.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3416897     DOI: 10.1016/0277-5379(88)90118-6

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  6 in total

1.  Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.

Authors:  G Minotti; M Parlani; E Salvatorelli; P Menna; A Cipollone; F Animati; C A Maggi; S Manzini
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

2.  Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.

Authors:  C Agen; N Bernardini; R Danesi; P Della Torre; M Costa; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Kinetic analysis of saturable myocardial uptake of idarubicin in rat heart: effect of doxorubicin and hypothermia.

Authors:  Wonku Kang; Michael Weiss
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

4.  Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.

Authors:  B J Cusack; S P Young; J Driskell; R D Olson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Improved In Vivo Anti-Tumor and Anti-Metastatic Effect of GnRH-III-Daunorubicin Analogs on Colorectal and Breast Carcinoma Bearing Mice.

Authors:  Ivan Ranđelović; Sabine Schuster; Bence Kapuvári; Gianluca Fossati; Christian Steinkühler; Gábor Mező; József Tóvári
Journal:  Int J Mol Sci       Date:  2019-09-25       Impact factor: 5.923

6.  Visualisation of doxorubicin in human and animal tissues and in cell cultures by immunogold-silver staining.

Authors:  H P Henneberry; G W Aherne
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.